Efforts to open a retail marijuana dispensary in Westerly after a developer abandoned plans for the former Wendy’s on Route 1 ...

A successful GenAI launch requires diligent planning, robust governance and adaptation. It’s about thoughtfully integrating ...

An interview with Allan Thygesen, CEO of Docusign, about the e-signature vendor's repositioning to use AI to digitize ...

In the evening light and as grey clouds circled Headingley, England pulled off another miraculous triumph with a performance ...

For decades, Eugeneans have been dreaming of a space in town that connects the Willamette River to urban resources like parks ...

Intervals are reported with no more than 3 m of internal dilution of less than 0.3 g/t Au except ... and Kadie Zones. The latest phase of drilling has further refined structural controls on gold ...

HIGHLIGHTS <li /> 52m @ 16.4 g/t gold from 256m downhole in hole OEDD-148, including 11m @ 70.3 g/t gold from 279m ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday.. A total of 106 patients with ...